close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

Leading Academics and Industry Leaders to Keynote at Dedicated Co-Crystals Conference

Pharmaceutical Co-Crystals
September 24 - 26, 2007

Radisson SAS Hotel (Amsterdam), Amsterdam, Netherlands

 

LONDON, July 6, 2007--As this special issue of C&EN indicates, the field of pharmaceutical co-crystals presents a very exciting opportunity for the pharmaceutical industry. The promise of new intellectual property and improved performance has created a huge amount of interest, but many people have been struggling to find their way in such a quickly developing area.


Now, industry is beginning to make the most of the benefits of co-crystals. And first time case studies will be presented at Pharmaceutical Co-crystals. Pharma IQ is proud to bring together the world’s leading experts in the area at this important meeting, which provides an unrivalled platform to assess the developments in the field, and understand how pharma can make the most of the potential that co-crystals can offer.


This 2007 meeting will include research updates from leading academics including Mike Zaworotko, Professor and Chairperson, Department of Chemistry, University of South Florida and Nair Rodriguez-Hornedo, Associate Professor, Department of Pharmaceutical Sciences, University of Michigan, as well as practical applications from leaders such as Scott Childs, Research Scientist, SSCI, an Aptuit Company.


Pharma IQ’s Pharmaceutical Co-Crystals 2007 is the only specific event for pharmaceutical scientists to explore the design and development of co-crystals.  It will build on success of last year’s pioneering meeting, of which Ashwini Nangia of the University of Hyderabad commented “Pharma co-crystals was the most informative meeting I have attended in recent times. Great job, well done. Thank you!”

 

For more information about this conference, early booking discounts or to register go to http://www.iqpc.com/nl/cocrystals/pharmalive or freephone 0800 652 2363 or +44 (0)20 7368 9300, or email amy.jeffray@iqpc.co.uk.

 

 

 

Amy Jeffray

Marketing Manager

IQPC Ltd.

www.iqpc.co.uk

 

P: +44 (0)20 7368 9306 | F: +44 (0)207 368 9303

Anchor House | 15-19 Britten Street | London SW3 3QL

 

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...